Suicide gene therapy for hepatocellular carcinoma cells by survivin promoter-driven expression of the herpes simplex virus thymidine kinase gene

Qu,Lili; Wang,Yanyun; Gong,Lailing; Zhu,Jin; Gong,Rujun; Si,Jin

doi:10.3892/or.2013.2248

Suicide gene therapy for hepatocellular carcinoma cells by survivin promoter-driven expression of the herpes simplex virus thymidine kinase gene

Authors:
- Lili Qu
- Yanyun Wang
- Lailing Gong
- Jin Zhu
- Rujun Gong
- Jin Si
View Affiliations

Affiliations: Department of Laboratory Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, P.R. China, Huadong Medical Institute of Biotechniques, Nanjing 210002, P.R. China, Department of Medicine, Brown Medical School, Providence, RI 02903, USA
Published online on: January 24, 2013 https://doi.org/10.3892/or.2013.2248
Pages: 1435-1440

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the selective killing effect of the herpes simplex virus-thymidine kinase/ganciclovir (TK/GCV) suicide gene system controlled by the survivin promoter on hepatocellular carcinoma (HCC) cells in vitro. Recombinant plasmid vectors driven by the survivin promoter were constructed. HepG2 HCC and LO2 normal human liver cells were transfected with the recombinant plasmids, green fluorescent protein (GFP)/pSURV, TK/pSURV and TAT-TK/pSURV. GFP expression was detected by fluoroscopy and flow cytometry (FCM). TK gene expression was detected using RT-PCR and western blot analysis. The selective killing effects after GCV application were evaluated by tetrazolium assay, FCM and western blot analysis. Statistical analysis was performed by ANOVA. After transfection with GFP/pSURV, TK/pSURV and TAT-TK/pSURV for 48 h, GFP expression was observed in the HepG2 cells, but not in the L02 cells and TK gene expression was evidently detected by RT-PCR and western blot analysis in the HepG2 cells. Three stably transfected cell lines (HepG2/pSURV, HepG2/TK/pSURV and HepG2/TAT-TK/pSURV) were successfully established. Compared with the HepG2/TK/pSURV group, a significant ‘bystander effect’ was observed in the HepG2/TAT-TK/pSURV group with the incorporation of unmodifed HepG2 cells at different ratios. Following transfection with TK/pSURV and TAT-TK/pSURV, the growth of HepG2 cells in the presence of GCV was markedly inhibited. This finding was further corroborated by FCM and immunoblot analysis revealed the repressed expression of proliferating cell nuclear antigen (PCNA). Our results showed that the plasmid vectors carrying the TK and TAT-TK fusion protein gene driven by the survivin promoter were successfully constructed and their specific expression in HepG2 cells provided the basis for the targeted gene therapy of HCC.

View Figures

View References

1	Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar
2	Okuda K: New trends in hepatocellular carcinoma. Int J Clin Lab Res. 23:173–178. 1993. View Article : Google Scholar
3	Bruix J, Boix L, Sala M and Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell. 5:215–219. 2004. View Article : Google Scholar
4	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
5	Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46:5276–5281. 1986.
6	Springer CJ and Niculescu-Duvaz I: Prodrug-activating systems in suicide gene therapy. J Clin Invest. 105:1161–1167. 2000. View Article : Google Scholar : PubMed/NCBI
7	Denny WA: Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy). J Biomed Biotechnol. 2003:48–70. 2003. View Article : Google Scholar : PubMed/NCBI
8	Schepelmann S and Springer CJ: Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther. 6:647–670. 2006. View Article : Google Scholar : PubMed/NCBI
9	Dietz GP and Bahr M: Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci. 27:85–131. 2004. View Article : Google Scholar : PubMed/NCBI
10	Gratton JP, Yu J, Griffith JW, et al: Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med. 9:357–362. 2003. View Article : Google Scholar : PubMed/NCBI
11	Lehmusvaara S, Rautsi O, Hakkarainen T and Wahifors J: Utility of cell-permeable peptides for enhancement of virus-mediated gene transfer to human tumor cells. Biotechniques. 40:573–576. 2006. View Article : Google Scholar : PubMed/NCBI
12	Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B and D’Souza GG: Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA. 100:1972–1977. 2003. View Article : Google Scholar : PubMed/NCBI
13	Li SD and Huang L: Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs. 9:1317–1323. 2008.PubMed/NCBI
14	Ambrosini G, Adida C, Sirugo G and Altieri DC: Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 273:11177–11182. 1998. View Article : Google Scholar : PubMed/NCBI
15	Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 22:8581–8589. 2003. View Article : Google Scholar : PubMed/NCBI
16	Ryan BM, O’Donovan N and Duffy MJ: Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
17	Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T and Altieri DC: Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res. 9:2683–2692. 2003.PubMed/NCBI
18	Sah NK, Khan Z, Khan GJ and Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
19	Ikeguchi M, Hirooka Y and Kaibara N: Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer. 95:1938–1945. 2002. View Article : Google Scholar : PubMed/NCBI
20	Chen JS, Liu JC, Shen L, et al: Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther. 11:740–747. 2004. View Article : Google Scholar : PubMed/NCBI
21	Chen SH, Kosai K, Xu B, et al: Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 56:3758–3762. 1996.PubMed/NCBI
22	Kieback DG, Fischer DC, Engehausen DG, et al: Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. Cancer Gene Ther. 9:478–481. 2002. View Article : Google Scholar : PubMed/NCBI
23	Qiu Z, Harms JS, Zhu J and Splitter GA: Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22. J Virol. 78:4224–4233. 2004. View Article : Google Scholar
24	Mizuguchi H and Hayakawa T: Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther. 9:236–242. 2002. View Article : Google Scholar
25	Kagaya T, Nakamoto Y, Sakai Y, et al: Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther. 13:357–366. 2006. View Article : Google Scholar
26	Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI
27	Li F and Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J. 344:305–311. 1999. View Article : Google Scholar
28	Bao R, Connolly DC, Murphy M, et al: Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst. 94:522–528. 2002. View Article : Google Scholar : PubMed/NCBI
29	Huang Q, Liu XZ, Kang CS, Wang GX, Zhong Y and Pu PY: The anti-glioma effect of suicide gene therapy using BMSC expressing HSV/TK combined with overexpression of Cx43 in glioma cells. Cancer Gene Ther. 17:192–202. 2010. View Article : Google Scholar : PubMed/NCBI
30	Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH and Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1550–1552. 1992. View Article : Google Scholar : PubMed/NCBI
31	Freeman SM, Abboud CN, Whartenby KA, et al: The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:5274–5283. 1993.
32	Touraine RL, Ishii-Morita H, Ramsey WJ and Blaese RM: The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 5:1705–1711. 1998. View Article : Google Scholar : PubMed/NCBI
33	Merilainen O, Hakkarainen T, Wahlfors T, Pellinen R and Wahlfors J: HIV-1 TAT protein transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFP triple fusion construct. Int J Oncol. 27:203–208. 2005.PubMed/NCBI
34	Vives E, Brodin P and Lebleu B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 272:16010–16017. 1997. View Article : Google Scholar
35	Schwarze SR and Dowdy SF: In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci. 21:45–48. 2000. View Article : Google Scholar : PubMed/NCBI
36	Bremner KH, Seymour LW and Pouton CW: Harnessing nuclear localization pathways for transgene delivery. Curr Opin Mol Ther. 3:170–177. 2001.PubMed/NCBI
37	Cao L, Si J, Wang W, et al: Intracellular localization and sustained prodrug cell killing activity of TAT-HSVTK fusion protein in hepatocelullar carcinoma cells. Mol Cells. 21:104–111. 2006.PubMed/NCBI